Akèy › Sklerodèm › Texas › Houston
Etid klinik pou Sklerodèm nan Houston, TX
9 etid pou Sklerodèm ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Ap rekriteFaz 3
- The University of Texas Health Science Center at Houston, Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
Platform Clinical Study for Conquering Scleroderma
Ap rekriteFaz 2
- University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Ap rekriteFaz 1/2
- Nkarta Investigational Site, Houston
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Ap rekriteFaz 2
- Artiva Investigational Site Bellaire, Bellaire · 7 mi lwen
A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis
Ap rekriteFaz 2
- The University of Texas Health Science Center at Houston, Houston
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Ap rekriteFaz 1/2
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
Ap rekrite
- The University of Texas Health Science Center at Houston, Houston
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Ap rekriteFaz 2
- aTyr Investigative Site, Houston
Etid Sklerodèm nan lòt vil
- New York City, NY11 etid
- Ann Arbor, MI10 etid
- Chicago, IL10 etid
- Los Angeles, CA7 etid
- Boston, MA7 etid
- Durham, NC7 etid
- New Orleans, LA6 etid
- Philadelphia, PA6 etid
- Baltimore, MD6 etid
- Dallas, TX5 etid
- Pittsburgh, PA5 etid
- Miami, FL4 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)122 etid
- Kansè Metastatik104 etid
- Kansè kolorektal103 etid
- Kansè ovè90 etid
- Leksemi mieloïd egi86 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt69 etid
- Kansè pankreyas62 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.